Novartis cancer med combats lymphoma

The Novartis kidney-cancer remedy Afinitor cut tumor size by 50 percent or more in a third of lymphoma patients in a mid-stage trial; the Swiss drugmaker has started a late-stage trial to evaluate disease-free survival in patients with that disease. Report

Suggested Articles

Amarin Vascepa pill
Pharma

Amarin's Vascepa sails through FDA panel vote toward new CV nod

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

by Kyle Blankenship
Fujifilm Diosynth Biotechnologies in Texas
Manufacturing

Fujifilm investing $120M in U.S. gene therapy operations

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

by Eric Palmer
Falcon 9 launch
Marketing

Intercept amps up sales force ahead of potential NASH rollout

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

by Eric Sagonowsky